John Gabrielson, senior vice president at JSR Life Sciences and head of Similis Bio, shares how the recent codevelopment deal between Similis and Blau Farmaceutica differs from commercialization and licensing deals many other companies have signed with each other.
John Gabrielson, senior vice president at JSR Life Sciences, offers insight into the recent codevelopment deal Similis signed with Blau Farmaceutica and his projections for how biosimilars will evolve in the coming years.
Transcript
Similis Bio recently signed its first codevelopment partnership with Blau Farmaceutica for 4 biosimilar products. How does this partnership differ from the common commercialization and licensing deals that the global biosimilars industry has been seeing increases of in recent years?
Gabrielson: Yeah, so, we're really excited about this partnership with Blau. And several features of this deal, I think, will benefit both parties in the long term. So, most importantly, Blau and JSR both have the incentive to make commercially successful biosimilars from the very beginning of the project to the very end to commercialization and market access.
We structured the deal as a hybrid development and licensing agreement. Some of the assets are ready to licensed immediately, and others were just starting now. So, as we've seen over the past 6 months or so as we've talked with biosimilar companies, we've learned that there's a robust global market for both fully developed preclinical biosimilars and then many companies are looking for co-development agreements. So, we combine those 2 approaches in this in this deal.
How do you expect the biosimilars market to develop in the future, especially as the United States prepares for the introduction of several adalimumab and ustekinumab biosimilars over the next couple years?
Gabrielson: Yeah, so thanks for the question. We will first continue to see price competition in the US as more biosimilars enter the market. I think most people know that, and I hope the pricing pressure will translate into cost savings for patients. Ultimately, that's our goal, and I think that's everyone's goal.
Some of the other changes are less obvious, like potential regulatory relief on clinical and nonclinical requirements. The softening of clinical conditions will necessarily lead to increasing preclinical requirements. Notably, as clinical requirements become more streamlined, we expect the rigor of analytical CMC [chemistry, manufacturing, and control] development, which is something similar says routinely to increase substantially as regulators place more emphasis on state of the art methodologies to characterize the biosimilar product.
Ultimately, this will lead to reduced residual uncertainty. The higher that we can make the bar for demonstration of analytical similarity between the biosimilar and the reference product, the higher the likelihood that the product will be ultimately approved.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.